Anticoagulation Beyond 3 to 6  Months: What Does the Data Tell Us?

Patients with a history of deep vein thrombosis and pulmonary embolism are at risk for a recurrent event. This is particularly true of patients with idiopathic events or events related to low risk triggers. In these patients extending anticoagulation beyond 3 to 6  months may be warranted. Using clinical risk, biomarker analysis and risk stratification protocols we can make the best recommendations to patients with respect to the risks and benefits of ongoing therapy. Trials demonstrating benefit from low-dose aspirin for secondary prophylaxis may provide a n option for patients in whom ongoing anticoagulation is deemed unsafe.
Source: Progress in Cardiovascular Diseases - Category: Cardiology Authors: Source Type: research